MAIA Biotechnology (MAIA) Non-Current Assets (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Non-Current Assets of $7518.0 for Q1 2026, up 168.5% year-over-year from $2800.0 in Q1 2025, and up 168.5% quarter-over-quarter from $2800.0 in Q4 2025.
MAIA Biotechnology (MAIA) Non-Current Assets (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Non-Current Assets for 6 consecutive years, with $7518.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 168.5% year-over-year to $7518.0; the TTM figure through Mar 2026 stood at $40203.0 (up 258.96% YoY), while the FY2025 annual figure was $2800.0, changed 0.0% from the prior year.
- Non-Current Assets climbed to $7518.0 in Q1 2026 per MAIA's latest filing, from $2800.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.2 million in Q2 2022 and bottomed at $2800.0 in Q3 2022.
- Historically, Non-Current Assets has averaged $189870.9 across 5 years, with a median of $5159.0 in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 13040.71% — and 2024, when it tumbled 99.43%.
- MAIA Biotechnology's Non-Current Assets stood at $214003.0 in 2022, then tumbled by 98.69% to $2800.0 in 2023, then changed by 0.0% to $2800.0 in 2024, then changed by 0.0% to $2800.0 in 2025, then surged by 168.5% to $7518.0 in 2026.
- Business Quant data shows MAIA's Non-Current Assets at $7518.0 in Q1 2026, $2800.0 in Q4 2025, and $27085.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | 2,800.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,800.00 |
| Mar 31, 2026 | 7,518.00 |
| Dec 31, 2025 | 2,800.00 |
| Sep 30, 2025 | 27,085.00 |
| Jun 30, 2025 | 2,800.00 |
| Mar 31, 2025 | 2,800.00 |
| Dec 31, 2024 | 2,800.00 |
| Sep 30, 2024 | 2,800.00 |
| Jun 30, 2024 | 2,800.00 |
| Mar 31, 2024 | 16,035.00 |
| Dec 31, 2023 | 2,800.00 |
| Sep 30, 2023 | 367,940.00 |
| Jun 30, 2023 | 492,449.00 |
| Mar 31, 2023 | 740,488.00 |
| Dec 31, 2022 | 214,003.00 |
| Sep 30, 2022 | 2,800.00 |
| Jun 30, 2022 | 1.15 Mn |
| Dec 31, 2021 | 654,704.00 |